Mechanisms and clinical implications of renal drug excretion

被引:91
作者
Masereeuw, R [1 ]
Russel, FGM [1 ]
机构
[1] Univ Med Ctr Nijmegen, Dept Pharmacol & Toxicol 233, NL-6500 HB Nijmegen, Netherlands
关键词
D O I
10.1081/DMR-120000654
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The body defends itself against potentially harmful compounds like drugs, toxic compounds, and their metabolites by elimination, in which the kidney plays an important role. Renal clearance is used to determine renal elimination mechanisms of a drug, which is the result of glomerular filtration, active tubular secretion and reabsorption. The renal proximal tubule is the primary site of carrier-mediated transport from blood to urine. Renal secretory mechanisms exists for, anionic compounds and organic cations. Both systems comprises several transport proteins, and knowledge of the molecular identity of these transporters and their substrate specificity has increased considerably in the past decade. Due to overlapping specificities of the transport proteins, drug interactions at the level of tubular secretion is an event that may occur in clinical situation. This review describes the different processes that determine renal drug handling, the techniques that have been developed to attain more insight in the various aspects of drug excretion, the functional characteristics of the individual transport proteins, and finally the implications of drug interactions in a clinical perspective.
引用
收藏
页码:299 / 351
页数:53
相关论文
共 395 条
[91]  
FUJITA K, 1985, INT J CLIN PHARM TH, V23, P288
[92]   EFFECT OF ASPIRIN AND SULINDAC ON METHOTREXATE CLEARANCE [J].
FURST, DE ;
HERMAN, RA ;
KOEHNKE, R ;
ERICKSEN, N ;
HASH, L ;
RIGGS, CE ;
PORRAS, A ;
VENGPEDERSEN, P .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1990, 79 (09) :782-786
[93]   Valacycloviv: A substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2 [J].
Ganapathy, ME ;
Huang, W ;
Wang, H ;
Ganapathy, V ;
Leibach, FH .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1998, 246 (02) :470-475
[94]   Interaction of anionic cephalosporins with the intestinal and renal peptide transporters PEPT 1 and PEPT 2 [J].
Ganapathy, ME ;
Prasad, PD ;
Mackenzie, B ;
Ganapathy, V ;
Leibach, FH .
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 1997, 1324 (02) :296-308
[95]   DIFFERENTIAL RECOGNITION OF BETA-LACTAM ANTIBIOTICS BY INTESTINAL AND RENAL PEPTIDE TRANSPORTERS, PEPT-1 AND PEPT-2 [J].
GANAPATHY, ME ;
BRANDSCH, M ;
PRASAD, PD ;
GANAPATHY, V ;
LEIBACH, FH .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (43) :25672-25677
[96]  
GEKLE M, 1994, RENAL PHYSIOL BIOCH, V17, P40
[97]   Inhibition of initial transport rate of basolateral organic anion carrier in renal PT by BK and phenylephrine [J].
Gekle, M ;
Mildenberger, S ;
Sauvant, C ;
Bednarczyk, D ;
Wright, SH ;
Dantzler, WH .
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 1999, 277 (02) :F251-F256
[98]  
Gilsdorf JS, 1997, J PHARMACOL EXP THER, V280, P1043
[99]   THE EFFECT OF PROBENECID ON THE RENAL ELIMINATION OF CIMETIDINE [J].
GISCLON, LG ;
BOYD, RA ;
WILLIAMS, RL ;
GIACOMINI, KM .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 45 (04) :444-452
[100]  
Goldberg J. P., 1985, The Kidney: Physiology and Pathophysiology, P2097